Piretanide

Summary

Piretanide (CHEMBL349803) is an approved small molecule (ATC C03CA03) targeting SLC12A1 and SLC12A2; indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C03CA03
• Targets: 2 (SLC12A1, SLC12A2)
• Indications: 1 condition
• Chemistry: 362.4 Da · C17H18N2O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL349803
Name	Piretanide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4849
ATC	C03CA03
Molecular formula	C17H18N2O5S
Molecular weight	362.4
InChIKey	UJEWTUDSLQGTOA-UHFFFAOYSA-N

SMILES: C1CCN(C1)C2=C(C(=CC(=C2)C(=O)O)S(=O)(=O)N)OC3=CC=CC=C3

IUPAC name: 4-phenoxy-3-pyrrolidin-1-yl-5-sulfamoylbenzoic acid

Also known as: Arelix, HOE 118, HOE-118, Piretanida, Piretanide, S 73 4118, S-734118, SID11112792, SID56463166, PIRETANIDE, SID170465869, SID144204212

Patent coverage: 1,707 distinct patent families (6,792 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 6,790 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SLC12A1	Kidney-specific Na-K-Cl symporter	Inhibition	5.97	0.6%	Q13621
SLC12A2	Basolateral Na-K-Cl symporter	Inhibition	5.62	0.1%	P55011

Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Lysine-specific demethylase 4E, Ubiquitin carboxyl-terminal hydrolase 2, Prelamin-A/C, Ferritin light chain, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Sodium-dependent serotonin transporter, Aldehyde dehydrogenase 1A1, 3-hydroxyacyl-CoA dehydrogenase type-2, Hypoxia-inducible factor 1-alpha.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 10 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	8.4	Potency	4	nM	CHEMBL_ACT_3653407
SLC6A4	6.04	AC50	920	nM	CHEMBL_ACT_25149974
HIF1A	6	Potency	1000	nM	CHEMBL_ACT_4128845
HIF1A	6	Potency	1000	nM	CHEMBL_ACT_4520667
P02791	5.35	Potency	4467	nM	CHEMBL_ACT_4492407
USP2	5.1	Potency	7943	nM	CHEMBL_ACT_4752051
ALDH1A1	5.05	Potency	8912	nM	CHEMBL_ACT_4181876

Target pathways

Aggregated over 2 target gene(s): SLC12A1, SLC12A2.

Top Reactome pathways

8 total, by targets touching each:

Pathway	Targets	Genes
Transport of small molecules	2	SLC12A1, SLC12A2
R-HSA-425393	2	SLC12A1, SLC12A2
SLC-mediated transmembrane transport	2	SLC12A1, SLC12A2
Cation-coupled Chloride cotransporters	2	SLC12A1, SLC12A2
Disease	1	SLC12A1
SLC transporter disorders	1	SLC12A1
Defective SLC12A1 causes Bartter syndrome 1 (BS1)	1	SLC12A1
Disorders of transmembrane transporters	1	SLC12A1

Dominant GO biological processes

GO term	Targets
monoatomic ion transport	2
cell volume homeostasis	2
sodium ion transmembrane transport	2
chloride ion homeostasis	2
potassium ion homeostasis	2
sodium ion homeostasis	2
transepithelial ammonium transport	2
chloride transmembrane transport	2
potassium ion import across plasma membrane	2
potassium ion transport	2
sodium ion transport	2
transmembrane transport	2
potassium ion transmembrane transport	2
monoatomic ion transmembrane transport	1
ammonium homeostasis	1

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

2 molecules share ≥1 primary target. Top 2 by shared-target count:

Molecule	Source	Status	Shared targets
Bumetanide	ChEMBL + PubChem	Phase 4 (approved)	SLC12A1, SLC12A2
Furosemide	PubChem	Approved	SLC12A1, SLC12A2